• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by MiNK Therapeutics Inc. (Amendment)

    5/3/23 5:23:56 PM ET
    $INKT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INKT alert in real time by email
    SC 13D/A 1 d323987dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    MINK THERAPEUTICS, INC.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    603693102

    (CUSIP Number)

    Garo H. Armen, Ph.D.

    Chairman and CEO

    Agenus Inc.

    3 Forbes Road

    Lexington, MA 02421

    (781) 674-4400

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    May 1, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box  ☐.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13D

     

    CUSIP No. 45249V 107    Page 2 of 4 Pages

     

      1    

      NAME OF REPORTING PERSONS

     

      Agenus Inc. (“Agenus”)

      2  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

      (a)  ☐        (b)  ☐

     

      3  

      SEC USE ONLY

     

      4  

      SOURCE OF FUNDS (See Instructions)

     

      WC

      5  

      CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

     

      ☐

      6  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

         7    

      SOLE VOTING POWER

     

      21,344,685

         8  

      SHARED VOTING POWER

     

         9  

      SOLE DISPOSITIVE POWER

     

      21,344,685

       10  

      SHARED DISPOSITIVE POWER

     

    11    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      21,344,685

    12  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)

     

      ☐

    13  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

      62% (1)

    14  

      TYPE OF REPORTING PERSON (See Instructions)

     

      CO

     

    (1)

    This percentage is calculated based upon 33,910,688 shares of the Issuer’s Common Stock reported to be outstanding as of March 15, 2025, as disclosed in the Issuer’s Annual Report on For m 10-K filed with the Securities and Exchange Commission on March 24, 2023.


    Page 3 of 4 Pages

     

    Explanatory Note

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (“SEC”) on October 28, 2021 (the “Schedule 13D”), relating to the common stock, par value $0.00001 per share (“Common Stock”) of MiNK Therapeutics, Inc., a Delaware corporation (the “Issuer”). Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule 13D. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D.

    Item 5. Interest in Securities of the Issuer

    The information set forth in or incorporated by reference in Items 2, 3 and 4 of this Schedule 13D is incorporated by reference in its entirety into this Item 5.

     

      (a)

    See responses to Items and 13 on the cover page.

     

      (b)

    Agenus has sole power to vote and dispose of the securities of the Issuer held by it.

     

      (c)

    On May 1, 2023, Agenus paid its previously announced pro rata stock dividend (the “Dividend”) consisting of an aggregate of 4,988,081 shares of Common Stock held by Agenus (the “Dividend Shares”) to record holders of Agenus’s common stock (such stock, the “Agenus Common Stock”) as of April 17, 2023 (the “Record Date”). Agenus distributed 0.0146 of a share of the Common Stock for each share of Agenus Common Stock outstanding as of the close of business on the Record Date. No fractional shares were issued in connection with the Dividend and the equityholders of Agenus who were entitled to receive fractional shares of the Dividend Stock received cash (without interest) in lieu of such fractional shares and 192 shares of Common Stock owned by Agenus that represented the aggregate number of fractional shares that would have been distributed were retired.

     

      (d)

    Not applicable

     

      (e)

    Not applicable.


    Page 4 of 4 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: May 3, 2023     Agenus Inc.
        By:  

    /s/ Garo H. Armen, Ph.D.

        Name: Garo H. Armen, Ph.D.
        Title: Chairman and CEO
    Get the next $INKT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INKT

    DatePrice TargetRatingAnalyst
    1/24/2022$24.00 → $10.00Buy
    B. Riley Securities
    11/9/2021$24.00Buy
    B. Riley Securities
    11/9/2021$26.00Outperform
    Robert W. Baird
    11/9/2021Outperform
    William Blair
    11/9/2021$30.00Outperform
    Evercore ISI Group
    11/9/2021$26.00Outperform
    Baird
    More analyst ratings

    $INKT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

      NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 982

      5/5/25 12:30:00 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. "Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders," said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK The

      3/18/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

      NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada

      3/4/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Agenus Inc bought $25,270 worth of shares (22,975 units at $1.10), increasing direct ownership by 0.11% to 21,772,863 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      10/16/23 5:49:39 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Inc bought $16,380 worth of shares (15,001 units at $1.09), increasing direct ownership by 0.07% to 21,749,888 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      10/6/23 4:26:25 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley Securities reiterated coverage on MiNK Therapeutics with a new price target

      B. Riley Securities reiterated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $10.00 from $24.00 previously

      1/24/22 8:57:46 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B. Riley Securities initiated coverage on MiNK Therapeutics with a new price target

      B. Riley Securities initiated coverage of MiNK Therapeutics with a rating of Buy and set a new price target of $24.00

      11/9/21 7:57:17 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Robert W. Baird initiated coverage on MiNK Therapeutics with a new price target

      Robert W. Baird initiated coverage of MiNK Therapeutics with a rating of Outperform and set a new price target of $26.00

      11/9/21 7:17:32 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kadlec Robert Peter was granted 1,536 shares, increasing direct ownership by 125% to 2,764 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:15 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Behner Peter was granted 1,849 shares, increasing direct ownership by 14% to 15,209 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:14 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wiinberg Ulf was granted 1,593 shares, increasing direct ownership by 11% to 16,007 units (SEC Form 4)

      4 - MiNK Therapeutics, Inc. (0001840229) (Issuer)

      3/5/25 4:05:11 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INKT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by MiNK Therapeutics Inc.

      DEF 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)

      4/30/25 4:08:04 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form PRE 14A filed by MiNK Therapeutics Inc.

      PRE 14A - MiNK Therapeutics, Inc. (0001840229) (Filer)

      4/18/25 4:30:05 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by MiNK Therapeutics Inc.

      10-K - MiNK Therapeutics, Inc. (0001840229) (Filer)

      3/18/25 5:03:49 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INKT
    Leadership Updates

    Live Leadership Updates

    See more
    • MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

      NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics ((MiNK, NASDAQ:INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT) cell therapies, today announced the appointment of Dr. Robert Kadlec to its Board of Directors. Dr. Kadlec brings unparalleled expertise in biodefense, pandemic preparedness, and public health strategy, positioning MiNK to accelerate its innovative iNKT cell platform for addressing critical infectious diseases, including pathogen-agnostic acute respiratory distress syndrome (ARDS), emerging threats, and immune related diseases. Dr. Kadlec recently served as the U.S. Senate-confirmed Assistant

      10/31/24 9:15:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

      Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board Observer NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that it has entered into a stock purchase agreement to sell securities in a private placement financing (PIPE) for $5.8 million. This capital injection is e

      5/13/24 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INKT
    Financials

    Live finance-specific insights

    See more

    $INKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

      NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its first quarter 2025 financial results before the market opens on Thursday, May 15th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada) Conference ID: 982

      5/5/25 12:30:00 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

      NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. "Throughout 2024, MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe immune-related disorders," said Dr. Jennifer Buell, President and Chief Executive Officer of MiNK The

      3/18/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

      NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and year end 2024 financial results before the market opens on Tuesday, March 18th. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 (New York), 800-715-9871 (USA & Canada

      3/4/25 7:30:00 AM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by MiNK Therapeutics Inc.

      SC 13G - MiNK Therapeutics, Inc. (0001840229) (Subject)

      5/22/24 4:33:15 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by MiNK Therapeutics Inc.

      SC 13D - MiNK Therapeutics, Inc. (0001840229) (Subject)

      2/14/24 6:05:43 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by MiNK Therapeutics Inc. (Amendment)

      SC 13D/A - MiNK Therapeutics, Inc. (0001840229) (Subject)

      5/26/23 5:03:14 PM ET
      $INKT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care